Table 4 Summary of a Phase I CAR NK cell clinical trial targeting CD19
From: CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
NK source | Target antigen | CAR structure | Additional structure | Vector | Total patients | Diseases | Major findings | |||
|---|---|---|---|---|---|---|---|---|---|---|
CAR structure | Spacer | TM domain | Intracellular domain | |||||||
HLA-unmatched cord blood | CD19 | Anti-CD19 scFV | IgG1-CH2CH3 portion | CD28 | CD3ζ | IL-15, inducible caspase 9 | retroviral | 11 | CLL: 4; CLL with Richter’s transformation: 1; follicular lymphoma: 4; DLBCL: 2 | • No GVHD • No cytokine releasing syndrome, neurotoxicity, hemophagocytic lymphohistiocytosis • 8/11 complete response • CAR NK cells persisted ≥12 months |